Demonstration Environment - development


Structure of the Plasmodium falciparum PfA-M17_BES

Monash University
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=hdl:102.100.100/139&rft.title=Structure of the Plasmodium falciparum PfA-M17_BES&rft.identifier=3KR4&rft.publisher=Monash University&rft.description=&rft.creator=Anonymous& and Cell Biology&rft_subject=Biological Sciences&rft_subject=Medical Biochemistry and Metabolomics&rft_subject=Medical and Health Sciences&rft_subject=Macromolecular Crystallography&rft_subject=Diffraction&rft_subject=Protein Structure&rft_subject=X-ray&rft_subject=Synchrotron&rft.type=dataset&rft.language=English Go to Data Provider

Contact Information

Monash University


Current therapeutics and prophylactics for malaria are under severe challenge as a result of the rapid emergence of drug-resistant parasites. The human malaria parasite Plasmodium falciparum expresses two neutral aminopeptidases, PfA-M1 and PfA-M17, which function in regulating the intracellular pool of amino acids required for growth and development inside the red blood cell. These enzymes are essential for parasite viability and are validated therapeutic targets. We previously reported the X-ray crystal structure of the monomeric PfA-M1 and proposed a mechanism for substrate entry and free amino acid release from the active site. Here we present the X-ray crystal structure of the hexameric leucine aminopeptidase, PfA-M17, alone and in complex with two inhibitors with anti-malarial activity. The six active sites of the PfA-M17 hexamer are arranged in a disc-like fashion so that they are orientated inwards to form a central catalytic cavity; flexible loops that sit at each of the six entrances to the catalytic cavern function to regulate substrate access. In stark contrast to PfA-M1, PfA-M17 has a narrow and hydrophobic primary specificity pocket which accounts for its highly restricted substrate specificity. We also explicate the essential roles for the metal-binding centres in these enzymes (two in PfA-M17 and one in PfA-M1) in both substrate and drug binding. Our detailed understanding of the PfA-M1 and PfA-M17 active sites now permits a rational approach in the development of a novel class of two-target and/or combination anti-malarial therapy.

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover